Agreement signed with Aeterna Zentaris GmbH for European Rights to Macimorelin

Consilient Health are pleased to announce an exclusive agreement to licence macimorelin acetate 60mg for Europe, from Aeterna Zentaris GmbH, a wholly-owned subsidiary of Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS), a specialty biopharmaceutical company commercialising and developing therapeutics and diagnostic tests.

Ahmed Al-Derzi, Consilient Health’s CEO commented, “We are delighted to build this partnership with Aeterna Zentaris for macimorelin. Not only does the brand further strengthen our growing offering to endocrinology specialists and their patients but it also strengthens CH’s position across Europe. Macimorelin Aeterna Zentaris is an exciting innovation in the field of growth hormone deficiency.”

Commenting on the agreement Dr Klaus Paulini the President and CEO of Aeterna Zentaris said, “This license agreement represents another significant milestone for the Company as we continue to secure and bolster our portfolio of marketing partners for macimorelin in key markets. As a synergistic partner of choice with insight and commercialisation capabilities, we believe that Consilient Health brings noteworthy expertise that is the right fit for Aeterna Zentaris. We are grateful for their partnership and look forward to leveraging their experience in driving innovative marketing to our international distribution network for macimorelin.”

View more news and events